RO6889450 + Placebo + Risperidone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia, Schizoaffective Disorder
Conditions
Schizophrenia, Schizoaffective Disorder
Trial Timeline
Sep 8, 2020 → Jun 21, 2022
NCT ID
NCT04512066About RO6889450 + Placebo + Risperidone
RO6889450 + Placebo + Risperidone is a phase 2 stage product being developed by Roche for Schizophrenia, Schizoaffective Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04512066. Target conditions include Schizophrenia, Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia, Schizoaffective Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04512066 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia, Schizoaffective Disorder